Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

The vaccine contains inactivated viral antigens from the selected influenza strains. After injection, these antigens are taken up by antigen‑presenting cells, which trigger T‑cell activation and stimulate B‑cells to produce strain‑specific antibodies. The resulting antibodies can neutralise the corresponding influenza viruses, providing protective immunity.

The prescribed dose of Influvac is determined by a qualified healthcare professional. Typically, a single intramuscular (or subcutaneous) injection is administered each influenza season, but the exact volume and administration schedule are set by the prescriber based on local guidelines and patient factors.

Influvac may be administered to pregnant or breastfeeding individuals when the potential benefits outweigh any theoretical risks. Healthcare providers should evaluate each case individually, discuss the safety profile, and follow national recommendations regarding influenza vaccination during pregnancy and lactation.

To place an order, submit an enquiry on the Influvac product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Influvac is an inactivated, split‑virus vaccine that includes specific A (Victoria) and B (Austria) strains. Compared with live‑attenuated or recombinant influenza vaccines, it does not contain live virus and is suitable for a broader range of patients, including those with certain immunocompromising conditions. Efficacy and safety are comparable to other licensed seasonal influenza vaccines.

Influvac must be stored at 2 °C to 8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking. Prior to use, inspect the product for any discoloration or particulate matter and discard if the integrity is compromised.

Influvac is given by a single intramuscular or subcutaneous injection, usually into the deltoid muscle of the upper arm. The administration should be performed by a qualified healthcare professional using aseptic technique, following the dosage and site‑selection guidelines provided in the product’s prescribing information.

Serious adverse events, although rare, can include anaphylaxis, Guillain‑Barré syndrome, severe local reactions, high‑grade fever lasting more than 48 hours, and very rare thrombotic complications. Patients should be observed for a short period after vaccination and instructed to seek immediate medical attention if they experience symptoms such as difficulty breathing, swelling of the face or throat, or sudden weakness.

Influvac should be avoided in individuals with a documented severe allergy to any component of the vaccine or to a previous dose of an influenza vaccine. It is also contraindicated in persons who have experienced a severe allergic reaction (e.g., anaphylaxis) after a prior influenza immunisation. Clinicians should assess each patient’s medical history before vaccination.